Hitchhiking Cancer Vaccine Makes Progress in the Clinic
February 16, 2024
February 16, 2024
CAMBRIDGE, Massachusetts, Feb. 16 (TNSres) -- The Massachusetts Institute of Technology issued the following news:
* * *
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
* * *
By Bendta Schroeder, Koch Institute
Therapeutic cancer vaccines are an appealing strategy for treating malignancies. In th . . .
* * *
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
* * *
By Bendta Schroeder, Koch Institute
Therapeutic cancer vaccines are an appealing strategy for treating malignancies. In th . . .